Ophthalmology

Part 1: Samsung Bioepis Executive Shares Developer Perspective on Biosimilar Switching Studies, Clinical Efficacy Testing

January 23rd 2023

By The Center for Biosimilars Staff

As part of a series of interviews, Kyung-Ah Kim, executive vice president of Samsung Bioepis, offered insight into how developers view the current biosimilars market, the relevance of interchangeability, and the usefulness of clinical efficacy testing.

UK Authorizes New Lucentis Biosimilar, Ximluci

January 17th 2023

By Skylar Jeremias

The United Kingdom has approved STADA Arzneimittel and Xbrane Biopharma’s Ximluci, a ranibizumab biosimilar referencing Lucentis, for the treatment of retinal conditions.

Dr Michael Chiang: How the National Eye Institute Is Building Confidence in Ophthalmology Biosimilars

January 15th 2023

By Skylar Jeremias

Michael Chiang, MD, director of the National Eye Institute, discusses how his team is working to instill greater confidence in ophthalmology biosimilars among wary ophthalmologists.

Biosimilar Business Recap: Coherus Acquires Aflibercept; CRL for Biocon Biologics; Biosimilar Insulin Updates

January 11th 2023

By Skylar Jeremias

Coherus Biosciences has acquired an aflibercept biosimilar; the FDA has sent Biocon Biologics a complete response letter (CRL) regarding its insulin biosimilar; Lannett provides an update on the development of its insulin glargine and insulin aspart biosimilars.

Dr Chelsee Jensen Speaks on How Health Systems Can Build Confidence in Biosimilars

January 8th 2023

By Skylar Jeremias

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains what health organizations and health systems can do to better manage and instill confidence in biosimilars.

The Top 5 Ophthalmology Articles of 2022

January 2nd 2023

By Skylar Jeremias

Biosimilar news in ophthalmology throughout the year tended to focus on the advancements of ranibizumab biosimilars, such as the US launch of Byooviz, the recall of a biobetter of ranibizumab, and the UK approval of Ongavia.

Biogen's Ian Henshaw: Why Global Biosimilars Week Is Important for Improving Adoption

December 22nd 2022

By Skylar Jeremias

Ian Henshaw, senior vice president and global head of biosimilars at Biogen, describes the importance of awareness campaigns like the International Generic and Biosimilar Medicines Association's Global Biosimilars Week and how these initiatives can be leveraged to improve biosimilar adoption and acceptance.

New Year, New Hurdles: What's in Store for Biosimilars in 2023

December 18th 2022

By Skylar Jeremias

On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.

The European Union Gains Another Ranibizumab Biosimilar

November 15th 2022

By Skylar Jeremias

The European Union has approved a third biosimilar referencing Lucentis (ranibizumab), STADA Arzneimittel and Xbrane BioPharma’s Ximluci, for the treatment of retinal conditions.

In Sight: The Future of Biosimilars in Ophthalmology Care

November 14th 2022

A moderated digital open forum facilitated an interactive discussion among health care professionals, health system executives, health care payers, and health policy influencers about promise and the barriers to the expanded use of biosimilars in ophthalmic applications.